<DOC>
	<DOCNO>NCT01341899</DOCNO>
	<brief_summary>Type 1 diabetes autoimmune disease result T cell autoimmunity mediate destruction majority insulin-producing pancreatic β-cells . Hence , development new therapy control T cell autoimmunity , preserve remain β-cell function great significance manage patient type 1 diabetes Autologous nonmyeloablative hematopoietic stem cell transplantation ( AHST ) test treatment patient new onset type 1 diabetes . This therapeutic strategy result exogenous insulin independence destroy pathogenic memory T cell preserve remain β-cell function . However , little known efficacy AHST dynamic immunocompetent cell reconstitution reconstitute immune system regulate β-cell specific antibody response . Furthermore , many Chinese patient diagnosis type 1 diabetes progress develop diabetic ketoacidosis ( DKA ) . Whether treatment AHST could still achieve adequate glycemic control preserve β-cell function factor associate therapeutic efficacy explore . This phase Ⅱ clinical trial patient diagnose type 1 diabetes within previous 12 months.This study determine : - The effect autologous hematopoietic stem cell transplantation reconstitution immune system - β-cell preservation follow stem cell transplantation - The potential factor affect efficacy stem cell transplantation - Whether new therapy safe .</brief_summary>
	<brief_title>Efficacy Safety Study Autologous Hematopoietic Stem Cell Transplantation Treat New Onset Type 1 Diabetes</brief_title>
	<detailed_description>Patients diagnose type 1 diabetes within previous 12 month recruit study.Hematopoietic stem cell mobilize cyclophosphamide ( CY , 2.0g/m2 ) granulocyte colony stimulate factor ( 10 μg/kg per day ) collect peripheral blood leukapheresis cryopreserved . The cell infuse condition CY ( 200 mg/kg ) rabbit antithymocyte globulin ( 4.5 mg/kg ) . All include patient undergo AHST comply blood glucose self-monitoring schedule medical appointments.Their blood sample obtain measure frequency lymphocyte level plasma hemoglobin A1c ( HbA1c ) , serum C-peptide , islet antibody , cytokine longitudinally . Ages Eligible Study : 35 year Genders Eligible Study : Islet Autoantibodies Eligible Study : positive glutamic acid decarboxylase antibody ( GADA ) , protein tyrosine phosphatase antibody ( IA-2A ) , islet cell antibody ( ICA ) and/or insulin autoantibody ( IAAs )</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>diagnosis diabetes accord guideline World Health Organization 1999 duration diabetes 12 month positive glutamic acid decarboxylase antibody ( GADA ) , protein tyrosine phosphatase antibody ( IA2A ) , islet cell antibody ( ICA ) and/or insulin autoantibody ( IAAs ) pregnancy mental disorder blood disease presence severe disease could potentially influence transplantation outcome</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>stem cell</keyword>
	<keyword>C-peptide</keyword>
	<keyword>Immune function</keyword>
</DOC>